![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05
Axsome received a fast track designation from the FDA for AXS-05, developed for the treatment of agitation in patients with Alzheimer’s disease.
The drug is a combination of bupropion and dextromethorphan. Bupropion increases the bioavailability of dextromethorphan — an inhibitor of the serotonin and norepinephrine transporters.
Axsome Therapeutics previously received IND clearance from the FDA for a Phase II/III trial of AXS-05.
Upcoming Events
-
21Oct